167 related articles for article (PubMed ID: 14764677)
1. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele.
Karray S; Kress C; Cuvellier S; Hue-Beauvais C; Damotte D; Babinet C; Lévi-Strauss M
J Immunol; 2004 Feb; 172(4):2118-25. PubMed ID: 14764677
[TBL] [Abstract][Full Text] [Related]
2. TNF contributes to the immunopathology of perforin/Fas ligand double deficiency.
Cretney E; Street SE; Smyth MJ
Immunol Cell Biol; 2002 Oct; 80(5):436-40. PubMed ID: 12225379
[TBL] [Abstract][Full Text] [Related]
3. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.
Takahashi T; Tanaka M; Brannan CI; Jenkins NA; Copeland NG; Suda T; Nagata S
Cell; 1994 Mar; 76(6):969-76. PubMed ID: 7511063
[TBL] [Abstract][Full Text] [Related]
4. Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders.
Watanabe D; Suda T; Hashimoto H; Nagata S
EMBO J; 1995 Jan; 14(1):12-8. PubMed ID: 7530197
[TBL] [Abstract][Full Text] [Related]
5. Co-infusion of normal bone marrow partially corrects the gld T-cell defect. Evidence for an intrinsic and extrinsic role for Fas ligand.
Sobel ES; Kakkanaiah VN; Kakkanaiah M; Cohen PL; Eisenberg RA
J Immunol; 1995 Jan; 154(1):459-64. PubMed ID: 7527822
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NF-kappaB in T cells blocks lymphoproliferation and partially rescues autoimmune disease in gld/gld mice.
Vallabhapurapu S; Ryseck RP; Malewicz M; Weih DS; Weih F
Eur J Immunol; 2001 Sep; 31(9):2612-22. PubMed ID: 11536159
[TBL] [Abstract][Full Text] [Related]
7. In vivo depletion of Thy-1-positive cells originating from normal bone marrow abrogates the suppression of gld disease in normal-gld mixed bone marrow chimeras.
MacDonald GC; Kakkanaiah VN; Sobel ES; Cohen PL; Eisenberg RA
J Immunol; 1995 Jan; 154(1):444-9. PubMed ID: 7527820
[TBL] [Abstract][Full Text] [Related]
8. Gld mutation of Fas ligand increases the frequency and up-regulates cell survival genes in CD25+CD4+ TR cells.
Mohamood AS; Trujillo CJ; Zheng D; Jie C; Murillo FM; Schneck JP; Hamad AR
Int Immunol; 2006 Aug; 18(8):1265-77. PubMed ID: 16769751
[TBL] [Abstract][Full Text] [Related]
9. The accumulation of B220+ CD4- CD8- (DN) T cells in C3H-lpr/lpr mice is not accelerated by the stimulation of CD8+ T cells or B220+ DN T cells with staphylococcal enterotoxin B and occurs independently of V beta 8+ T cells.
Giese T; Davidson WF
Int Immunol; 1995 Aug; 7(8):1213-23. PubMed ID: 7495728
[TBL] [Abstract][Full Text] [Related]
10. Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion.
Pinkoski MJ; Droin NM; Lin T; Genestier L; Ferguson TA; Green DR
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16174-9. PubMed ID: 12454289
[TBL] [Abstract][Full Text] [Related]
11. Fas/Fas ligand deficiency results in altered localization of anti-double-stranded DNA B cells and dendritic cells.
Fields ML; Sokol CL; Eaton-Bassiri A; Seo S; Madaio MP; Erikson J
J Immunol; 2001 Aug; 167(4):2370-8. PubMed ID: 11490027
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
Roth E; Pircher H
J Immunol; 2004 Feb; 172(3):1588-94. PubMed ID: 14734739
[TBL] [Abstract][Full Text] [Related]
13. Amelioration of lymphoid hyperplasia and hypergammaglobulinemia in lupus-prone mice (gld) by Fas-ligand gene transfer.
Hong NM; Masuko-Hongo K; Sasakawa H; Kato T; Shirai T; Okumura K; Nishioka K; Kobata T
J Autoimmun; 1998 Aug; 11(4):301-7. PubMed ID: 9776707
[TBL] [Abstract][Full Text] [Related]
14. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
[TBL] [Abstract][Full Text] [Related]
15. Cellular interactions in the lpr and gld models of systemic autoimmunity.
Sobel ES
Adv Dent Res; 1996 Apr; 10(1):76-80. PubMed ID: 8934931
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity.
Medana I; Li Z; Flügel A; Tschopp J; Wekerle H; Neumann H
J Immunol; 2001 Jul; 167(2):674-81. PubMed ID: 11441070
[TBL] [Abstract][Full Text] [Related]
17. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts.
Tourneur L; Malassagne B; Batteux F; Fabre M; Mistou S; Lallemand E; Lores P; Chiocchia G
J Immunol; 2001 Aug; 167(3):1338-46. PubMed ID: 11466351
[TBL] [Abstract][Full Text] [Related]
18. Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis.
Batteux F; Lores P; Bucchini D; Chiocchia G
J Immunol; 2000 Feb; 164(4):1681-8. PubMed ID: 10657610
[TBL] [Abstract][Full Text] [Related]
19. The Nef-mediated AIDS-like disease of CD4C/human immunodeficiency virus transgenic mice is associated with increased Fas/FasL expression on T cells and T-cell death but is not prevented in Fas-, FasL-, tumor necrosis factor receptor 1-, or interleukin-1beta-converting enzyme-deficient or Bcl2-expressing transgenic mice.
Priceputu E; Rodrigue I; Chrobak P; Poudrier J; Mak TW; Hanna Z; Hu C; Kay DG; Jolicoeur P
J Virol; 2005 May; 79(10):6377-91. PubMed ID: 15858021
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype.
Körner H; Cretney E; Wilhelm P; Kelly JM; Röllinghoff M; Sedgwick JD; Smyth MJ
J Exp Med; 2000 Jan; 191(1):89-96. PubMed ID: 10620607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
